Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, 2835, 2023)

被引：0

作者：

Kirkwood, John M. ^{[1
]}

Del Vecchio, Michele ^{[2
]}

Weber, Jeffrey ^{[3
]}

Hoeller, Christoph ^{[4
]}

Grob, Jean-Jacques ^{[5
]}

Mohr, Peter ^{[6
]}

Loquai, Carmen ^{[7
]}

Dutriaux, Caroline ^{[8
]}

Chiarion-Sileni, Vanna ^{[9
]}

Mackiewicz, Jacek ^{[10
]}

Rutkowski, Piotr ^{[11
]}

Arenberger, Petr ^{[12
]}

Quereux, Gaelle ^{[13
]}

Meniawy, Tarek M. ^{[14
]}

Ascierto, Paolo A. ^{[15
]}

Menzies, Alexander M. ^{[16
]}

Durani, Piyush ^{[17
]}

Lobo, Maurice ^{[17
]}

Campigotto, Federico ^{[17
]}

Gastman, Brian ^{[18
]}

Long, Georgina V. ^{[16
]}

机构：

[1] UPMC Hillman Canc Ctr, Hillman Canc Ctr, Pittsburgh, PA 15232 USA

[2] Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[3] NYU, Langone Med Ctr, New York, NY USA

[4] Med Univ Wien, Vienna, Austria

[5] Hop La Timone, Marseille, France

[6] Elbe Klinikum Buxtehude, Buxtehude, Germany

[7] Univ Med Ctr Mainz, Mainz, Germany

[8] Hop St Andre, Bordeaux, France

[9] Ist Oncol Veneto, IOV IRCCS, Padua, Italy

[10] Poznan Univ Med Sci, Inst Oncol, Poznan, Poland

[11] Mar Sklodowska Curie Natl Res Inst Oncol, Gynecol Oncol, Warsaw, Poland

[12] Charles Univ Prague, Univ Hosp Kralovske Vinohrady, Fac Med 3, Dept Cardiol, Prague, Czech Republic

[13] Nantes Univ Hosp, Nantes, France

[14] Univ Western Australia, Sir Charles Gairdner Hosp, Perth, WA, Australia

[15] Ist Nazl Tumori IRCCS Fondaz G Pascale, Naples, Italy

[16] Univ Sydney, Royal North Shore & Mater Hosp, Melanoma Inst Australia, Sydney, NSW, Australia

[17] Bristol Myers Squibb, Princeton, NJ USA

[18] Cleveland Clin, Cleveland Hts, OH USA

来源：

NATURE MEDICINE | 2024年 / 30卷 / 03期

关键词：

D O I：

10.1038/s41591-023-02775-w

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

引用

页码：906 / 906

页数：1

共 50 条

[41] S-1 Based Doublet as ab Adjuvant Chemotherapy for Curatively Open Access Resected Stage III Gastric Cancer: Results from Randomized Phase III POST Trial
Lee, Choong-Kun
Jung, Minkyu
Kim, Hyo Song
Jung, Inkyung
Shin, Dong Bok
Kang, Seok Yun
Zang, Dae Young
Kim, Ki Hyang
Lee, Moon Flee
Kim, Bong-Seog
Lee, Kyung Hee
Cheong, Jae-Ho
Hyung, Woo Jin
Noh, Sung Noon
Chung, Hyun Cheol
Rha, Sun Young
CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 1 - 11
[42] First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
Bajorin, Dean F.
Witjes, Johannes Alfred
Gschwend, Jurgen
Schenker, Michael
Valderrama, Begona P.
Tomita, Yoshihiko
Bamias, Aristotelis
Lebret, Thierry
Shariat, Shahrokh
Park, Se Hoon
Ye Dingwei
Agerbaek, Mads
Collette, Sandra
Unsal-Kacmaz, Keziban
Zardavas, Dimitrios
Koon, Henry B.
Galsky, Matt D.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
[43] Adjuvant nivolumab plus ipilimumab (NIVO plus IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
Motzer, R. J.
Russo, P.
Gruenwald, V.
Tomita, Y.
Zurawski, B.
Parikh, O. A.
Buti, S.
Barthelemy, P.
Goh, J. C. H.
Ye, D.
Lingua, A.
Lattouf, J-B.
Escudier, B.
George, S.
Shuch, B.
Simsek, B.
Spiridigliozzi, J.
Chudnovsky, A.
Bex, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1430 - S1430
[44] EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial
Eggermont, A. M.
Suciu, S.
Santinami, M.
Kruit, W.
Testori, A.
Marsden, J.
Punt, C.
Hauschild, A.
Gore, M.
Keilholz, U.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[45] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Herbst, Roy S.
Wu, Yi-Long
John, Thomas
Grohe, Christian
Majem, Margarita
Wang, Jie
Kato, Terufumi
Goldman, Jonathan W.
Laktionov, Konstantin
Kim, Sang-We
Yu, Chong-Jen
Vu, Huu Vinh
Lu, Shun
Lee, Kye Young
Mukhametshina, Guzel
Akewanlop, Charuwan
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A.
Urban, Damien
Huang, Xiangning
Bolanos, Ana
Stachowiak, Marta
Tsuboi, Masahiro
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1830 - +
[46] Adjuvant pembrolizumab versus placebo in resected high- risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study
Khattak, Muhammad A.
Luke, Jason J.
Long, Georgina V.
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Robert, Caroline
Grob, Jean-Jacques
Merino, Luis de la Cruz
Del Vecchio, Michele
Spagnolo, Francesco
Mackiewicz, Jacek
Chiarion-Sileni, Vanna
Carlino, Matteo S.
Mohr, Peter
De Galitiis, Federica
Ross, Merrick I.
Eroglu, Zeynep
Chen, Ke
Jiang, Ruixuan
Fukunaga-Kalabis, Mizuho
Krepler, Clemens
Eggermont, Alexander M. M.
Kirkwood, John M.
EUROPEAN JOURNAL OF CANCER, 2022, 176 : 207 - 217
[47] Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial
Gschwend, J. E.
Bajorin, D.
Galsky, M.
Broughton, E.
Braverman, J.
Koon, H.
Maira-Arce, M.
Hamilton, M.
Shi, L.
Guo, S.
Witjes, J. A.
EUROPEAN UROLOGY, 2021, 79 : S1139 - S1140
[48] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Giacomo, Anna Maria Di
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
[49] Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
Becker, J. C.
Ugurel, S.
Leiter-Stoppke, U.
Meier, F.
Gutzmer, R.
Haferkamp, S.
Zimmer, L.
Livingstone, E.
Eigentler, T.
Hauschild, A.
Kiecker, F.
Hassel, J. C.
Mohr, P.
Fluck, M.
Thomas, I.
Garzarolli, M.
Grimmelmann, I.
Drexler, K.
Eckhardt, S.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S903 - S903
[50] Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial
Dummer, Reinhard
Brase, Jan C.
Garrett, James
Campbell, Catarina D.
Gasal, Eduard
Squires, Matthew
Gusenleitner, Daniel
Santinami, Mario
Atkinson, Victoria
Mandala, Mario
Chiarion-Sileni, Vanna
Flaherty, Keith
Larkin, James
Robert, Caroline
Kefford, Richard
Kirkwood, John M.
Hauschild, Axel
Schadendorf, Dirk
Long, Georgina, V
LANCET ONCOLOGY, 2020, 21 (03): : 358 - 372

← 1 2 3 4 5 →